A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with FcγR interactions. Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8 N/C EGa1, consisting of three anti-4-1BB single-chain variable fragments and three anti-EGFR single-domain antibodies positioned in an extended hexagonal conformation around the collagen XVIII homotrimerization domain. The1D8 N/C EGa1 trimerbody demonstrated high-avidity binding to 4-1BB and EGFR and a potent in vitro costimulatory capacity in the presence of EGFR. The trimerbody rapidly accumulates in EGFR-positive tumors and exhibits anti-tumor activity similar to IgG-based 4-1BB-agonistic mAbs. Importantly, treatment with 1D8 N/C EGa1 does not induce systemic inflammatory cytokine production or hepatotoxicity associated with IgG-based 4-1BB agonists. These results implicate FcγR interactions in the 4-1BB-agonist-associated immune abnormalities, and promote the use of the non-canonical antibody presented in this work for safe and effective costimulatory strategies in cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Targeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
Self-citationResults from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1272 · Cited by 424
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Yang, E. Y., & Shah, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01182 · Cited by 291
Claus, C., Ferrara, C., Xu, W., Sam, J., Lang, S., Uhlenbrock, F., Albrecht, R., Herter, S., Schlenker, R., Hüsser, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5989 · Cited by 270
Recombinant expression of nanobodies and nanobody-derived immunoreagents
de Marco, A. (2020) · Protein Expression and Purification · doi:10.1016/j.pep.2020.105645 · Cited by 137
“A paradigmatic example is offered by ALX-0171, an anti-viral therapeutic trimeric nanobody.”
Metadata
- Authors
- Compte, M., Harwood, S. L., Muñoz, I. G., Navarro, R., Zonca, M., Perez-Chacon, G., Erce-Llamazares, A., Merino, N., Tapia-Galisteo, A., Cuesta, A. M., Mikkelsen, K., Caleiras, E., Nuñez-Prado, N., Aznar, M. A., Lykkemark, S., Martínez-Torrecuadrada, J., Melero, I., Blanco, F. J., Bernardino de la Serna, J., Zapata, J. M., Sanz, L., & Alvarez-Vallina, L.
- Venue
- Nature Communications
- Published
- 2018-11-15
- Volume
- 9
- Issue
- 1
- Pages
- 4809-4809
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2900183473
- Cited by
- 142
- References
- 6
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. https://app.cochat.ai/papers/10.1038/s41467-018-07195-w
- The paper
- Compte, M., Harwood, S. L., Muñoz, I. G., Navarro, R., Zonca, M., Perez-Chacon, G., Erce-Llamazares, A., Merino, N., Tapia-Galisteo, A., Cuesta, A. M., Mikkelsen, K., Caleiras, E., Nuñez-Prado, N., Aznar, M. A., Lykkemark, S., Martínez-Torrecuadrada, J., Melero, I., Blanco, F. J., Bernardino de la Serna, J., . . . Alvarez-Vallina, L. (2018). A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. Nature Communications. https://doi.org/10.1038/s41467-018-07195-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.